Artios

Phase 1a dose escalation of ART0380 defined initial regimen to be evaluated in Phase 1b setting.Phase 1a dose escalation demonstrated a predictable safety profile and no unexpected safety findings supported by data from over 35…

Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios’ DDR-based platform…

Artios’ small molecule Polθ inhibitor elicits BRCA-gene synthetic lethality and PARP inhibitor synergyGenetic screening reveals biomarkers within the PARP inhibitor resistance setting to enable patient stratification in clinical…